Key facts
- 4C Medical’s last known valuation is $187.1M (Nov 2021).
- It has raised $165.1M across 6 recorded rounds; the latest was Later Stage VC ($71.6M) in Mar 2025.
- Notable investors include Yonghua Capital, Grant Park Ventures, AG Collective Capital, Anges Québec, Boston Scientific — 8 tracked in total.
- 4C Medical has filed 8 Form Ds with the SEC since 2016, most recently Mar 2025 ($71.6M sold to 80 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for 4C Medical
Funding rounds
6 roundsAbout 4C Medical
Developer of a novel minimally invasive system designed for the treatment of mitral regurgitation. The company's system directly addresses the complication without replacing the native mitral valve to preserve the native mitral annulus and left ventricle, enabling doctors to help patients get access to a minimally invasive alternative for the treatment of such complex conditions.
- Sector
- Healthcare
- HQ
- Maple Grove, MN, United States
- Founded
- 2015
- Employees
- 55
- Website
- 4cmed.com/
- Ownership
- Privately Held (backing)
4C Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 4C Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 4C Medical in its N-PORT filings yet. We sweep new filings monthly.